COX-2 inhibitors for the prevention of heterotopic ossification after THA

Orthopedics

Volumn 34, Issue 6, 2011, Pages

  Vasileiadis, George I ^a   Mavrogenis, ^a   Babis, ^a   Papagelopoulos, ^a   Vlasis, ^a   Sioutis, ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

DRUG EFFICACY; DRUG WITHDRAWAL; HETEROTOPIC OSSIFICATION; HUMAN; PERIOPERATIVE PERIOD; REVIEW; SYSTEMATIC REVIEW; TOTAL HIP PROSTHESIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 79958086633     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20110427-23     Document Type: Review

References (34)

1. Neal B, Gray H, McMahon S, Dunn L. Incidence of heterotopic ossification after major hip surgery. ANZ J Surg. 2002; 72(11):808-821. (Pubitemid 35370622)
2. Goel A, Sharp DJ. Heterotopic bone formation after hip replacement. The influence of the type of osteoarthritis. J Bone Joint Surg Br. 1991; 73(2):255-257.
3. Saudan M, Saudan P, Perneger T, Riand N, Keller A, Hoffmeyer P. Celecoxib versus ibuprofen in the prevention of heterotopic ossification following total hip replacement: a prospective randomised trial. J Bone Joint Surg Br. 2007; 89(2):155-159. (Pubitemid 46421457)
4. Ahrengart L, Lindgren U. Heterotopic bone after hip arthroplasty. Defining the patient at risk. Clin Orthop Relat Res. 1993;(293):153-159. (Pubitemid 23242864)
5. Naraghi FF, DeCoster TA, Moneim MS, Miller RA, Rivero D. Heterotopic ossification. Orthopedics. 1996; 19(2):145-151.
6. Sodemann B, Persson PE, Nilsson OS. Periarticular heterotopic ossification after total hip arthroplasty for primary coxarthrosis. Clin Orthop Relat Res. 1988; (237):150-157. (Pubitemid 19016051)
7. Kjaersgaard-Andersen P, Ritter MA. Prevention of formation of heterotopic bone after total hip arthroplasty. J Bone Joint Surg Am. 1991; 73(6): 942-947.
8. Brooker AF, Bowerman JW, Robinson RA, Riley LH Jr. Ectopic ossification following total hip replacement. Incidence and a method of classification. J Bone Joint Surg Am. 1973; (558):1629-1632.
9. Pellegrini VD Jr, Gregoritch SJ. Preoperative irradiation for prevention of heterotopic ossification following total hip arthroplasty. J Bone Joint Surg Am. 1996; 78(6):870-871.
10. Fransen M, Neal B. Non-steroidal anti-inflammatory drugs for preventing heterotopic bone formation after hip arthroplasty. Cochrane Database Syst Rev. 2004; (3):CD001160.
11. Raisz LG. Potential impact of selective cyclooxygenase-2 inhibitors on bone metabolism in health and disease. Am J Med. 2001; 110(Suppl 3A):43S-45S. (Pubitemid 32155402)
12. Kaplan-Machlis B, Klostermeyer BS. The cyclooxygenase-2 inhibitors: safety and effectiveness. Ann Pharmacother. 1999; 33(9):979-988. (Pubitemid 29420997)
13. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340(24):1888-1899. (Pubitemid 29272670)
14. van der Heide HJ, Koorevaar RT, Schreurs BW, van Kampen A, Lemmens A. Indomethacin for 3 days is not effective as prophylaxis for heterotopic ossification after primary total hip arthroplasty. J Arthroplasty. 1999; 14(7):796-799. (Pubitemid 29483244)
15. Cella JP, Salvati EA, Sculco TP. Indomethacin for the prevention of heterotopic ossification following total hip arthroplasty. Effectiveness, contraindications, and adverse effects. J Arthroplasty. 1988; 3(3):229-234.
16. Weber EW, Slappendel R, Durieux ME, Dirksen R, van der Heide H, Spruit M. COX 2 selectivity of non-steroidal anti-inflammatory drugs and perioperative blood loss in hip surgery. A randomized comparison of indomethacin and meloxicam. Eur J Anaesthesiol. 2003; 20(12):963-966. (Pubitemid 37500224)
17. van Tulder M, Furlan A, Bombardier C, Bouter L; Editorial Board of the Cochrane Collaboration Back Review Group. Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group. Spine (Phila Pa 1976). 2003; 28(12):1290-1299.
18. Grohs JG, Schmidt M, Wanivenhaus A. Selective COX-2 inhibitor versus indomethacin for the prevention of heterotopic ossification after hip replacement: a double-blind randomized trial of 100 patients with 1-year follow-up. Acta Orthop. 2007; 78(1):95-98. (Pubitemid 46570264)
19. van der Heide HJ, Rijnberg WJ, Van Sorge A, Van Kampen A, Schreurs BW. Similar effects of rofecoxib and indomethacin on the incidence of heterotopic ossification after hip arthroplasty. Acta Orthop. 2007; 78(1):90-94. (Pubitemid 46570263)
20. van der Heide HJ, Koorevaar RC, Lemmens JA, van Kampen A, Schreurs BW. Rofecoxib inhibits heterotopic ossification after total hip arthroplasty [published online ahead of print November 16, 2006]. Arch Orthop Trauma Surg. 2007; 127(7):557-561. (Pubitemid 47226169)
21. Romanò CL, Duci D, Romanò D, Mazza M, Meani E. Celecoxib versus indomethacin in the prevention of heterotopic ossification fter total hip arthroplasty. J Arthroplasty. 2004; 19(1):14-18. (Pubitemid 38112326)
22. Macfarlane RJ, Ng BH, Gamie Z, et al. Pharmacological treatment of heterotopic ossification following hip and acetabular surgery. Expert Opin Pharmacother. 2008; 9(5):767-786. (Pubitemid 351566193)
23. Vuolteenaho K, Moilanen T, Moilanen E. Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process [published online ahead of print October 31, 2007]. Basic Clin Pharmacol Toxicol. 2008; 102(1):10-14. (Pubitemid 350294081)
24. Buvanendran A, Kroin JS, Berger RA. Preoperative cyclooxygenase-2 inhibitor treatment reduces the incidence of heterotopic ossification after hip arthroplasty: six-month follow-up. Anesthesiology. 2007; 107(2):358-359. (Pubitemid 47196507)
25. Franchin F, Sanguineti F, Caione G. Preliminary study of rofecoxib (25 mg) in prevention of heterotopic ossification after total hip replacement. J Orthop Traumatol. 2004; 5(2):77-80. (Pubitemid 39232392)
26. Fijn R, Koorevaar RT, Brouwers JR. Prevention of heterotopic ossification after total hip replacement with NSAIDs. Pharm World Sci. 2003; 25(4):138-145. (Pubitemid 36987784)
27. Barthel T, Baumann B, Nöth U, Eulert J. Prophylaxis of heterotopic ossification after total hip arthroplasty: a prospective randomized study comparing indomethacin and meloxicam. Acta Orthop Scand. 2002; 73(6):611-614. (Pubitemid 36020901)
28. Vastel L, Rosencher N, Siney H, Courpied JP. Prevention of heterotopic ossifications in hip arthroplasty: effectiveness of selective COX-2 inhibitors (celecoxib) versus ketoprofen [in French]. Rev Chir Orthop Reparatrice Appar Mot. 2005; 91(1):64-69. (Pubitemid 40283452)
29. Persson PE, Nilsson OS, Berggren AM. Do non-steroidal anti-inflammatory drugs cause endoprosthetic loosening? A 10-year follow-up of a randomized trial on ibuprofen for prevention of heterotopic ossification after hip arthroplasty. Acta Orthop. 2005; 76(6):735-740.
30. Van Hecken A, Schwartz JI, Depré M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000; 40(10):1109-1120.
31. Whelton A, Fort JG, Puma JA, et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther. 2001; 8(2):85-95. (Pubitemid 33753522)
32. Lipsky PE, Brooks P, Crofford LJ, et al. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Intern Med. 2000; 160(7):913-920. (Pubitemid 30191918)
33. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [published online ahead of print February 15, 2005]. N Engl J Med. 2005; 352(11):1092-1102. (Pubitemid 40365350)
34. Oviedo JA, Schroy PC III. Does celecoxib use increase the risk of cardiovascular events? Gastroenterology. 2005; 129(4):1348-1350. (Pubitemid 41446873)